Chatree Chai-Adisaksopha1,2, Mark W Skinner2,3, Randall Curtis4, Neil Frick5, Michael B Nichol6, Declan Noone7, Brian O'Mahony7,8, David Page9, Jeffrey Stonebraker10, Lehana Thabane2,11, Mark A Crowther1,2, Alfonso Iorio1,2. 1. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. 3. Institute for Policy Advancement Ltd, Washington, District of Columbia. 4. Factor VIII Computing, Berkeley, California. 5. National Hemophilia Foundation, New York, New York. 6. Sol Price School of Public Policy, University of Southern California, Los Angeles, California. 7. Irish Haemophilia Society, Dublin, Ireland. 8. Trinity College Dublin, Dublin, Ireland. 9. Canadian Hemophilia Society, Montreal, Quebec, Canada. 10. Poole College of Management, North Carolina State University, Raleigh, North Carolina. 11. Biostatistics Unit, St Joseph's Healthcare, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The Patient Reported Outcomes, Burdens and Experiences (PROBE) study aims to develop and validate questionnaire for assessing health status in patients with haemophilia and participants without bleeding disorders. OBJECTIVE: To investigate the test-retest properties of the PROBE questionnaire. METHODS: The PROBE questionnaire covers four domains and is comprised of 29 questions. People with haemophilia (PWH) and participants without bleeding disorder were invited to participate in this study. All participants were asked to complete the PROBE questionnaire three times (paper-based survey on two consecutive days: T1 and T2 and then a web-based version: T3). Test-retest properties and percentage agreement were analysed. RESULTS: A total of 63 participants were enrolled in this study with a median age of 50 (range: 17-76) years. Of these, 30 (47.6%) were PWH. On the questions common to PWH and participants without bleeding disorder, Kappa coefficients ranged from 0.69 to 1.00, indicating substantial to almost perfect agreement (T1 vs T2). For haemophilia-related questions (T1 vs T2), Kappa coefficients ranged from 0.5 to 1.0. Of these, 5 of 11 items were in perfect agreement (Kappa = 1.0). The web-based questionnaire (T3) showed substantial to almost perfect agreement with the paper version (T1 test-retest properties were comparable between PWH and individuals without a bleeding disorder). CONCLUSIONS: The results suggest that PROBE is a reliable tool to assess patient-reported outcomes for PWH and benchmark data in participants without bleeding disorder. The web-based questionnaire and the standard paper-based version can be used interchangeably.
BACKGROUND: The Patient Reported Outcomes, Burdens and Experiences (PROBE) study aims to develop and validate questionnaire for assessing health status in patients with haemophilia and participants without bleeding disorders. OBJECTIVE: To investigate the test-retest properties of the PROBE questionnaire. METHODS: The PROBE questionnaire covers four domains and is comprised of 29 questions. People with haemophilia (PWH) and participants without bleeding disorder were invited to participate in this study. All participants were asked to complete the PROBE questionnaire three times (paper-based survey on two consecutive days: T1 and T2 and then a web-based version: T3). Test-retest properties and percentage agreement were analysed. RESULTS: A total of 63 participants were enrolled in this study with a median age of 50 (range: 17-76) years. Of these, 30 (47.6%) were PWH. On the questions common to PWH and participants without bleeding disorder, Kappa coefficients ranged from 0.69 to 1.00, indicating substantial to almost perfect agreement (T1 vs T2). For haemophilia-related questions (T1 vs T2), Kappa coefficients ranged from 0.5 to 1.0. Of these, 5 of 11 items were in perfect agreement (Kappa = 1.0). The web-based questionnaire (T3) showed substantial to almost perfect agreement with the paper version (T1 test-retest properties were comparable between PWH and individuals without a bleeding disorder). CONCLUSIONS: The results suggest that PROBE is a reliable tool to assess patient-reported outcomes for PWH and benchmark data in participants without bleeding disorder. The web-based questionnaire and the standard paper-based version can be used interchangeably.
Authors: Erna C van Balen; Brian O'Mahony; Marjon H Cnossen; Gerard Dolan; Victor S Blanchette; Kathelijn Fischer; Deborah Gue; Jamie O'Hara; Alfonso Iorio; Shannon Jackson; Barbara A Konkle; Diane J Nugent; Donna Coffin; Mark W Skinner; Cees Smit; Alok Srivastava; Fred van Eenennaam; Johanna G van der Bom; Samantha C Gouw Journal: Res Pract Thromb Haemost Date: 2021-03-06
Authors: Federico Germini; Victoria Borg Debono; David Page; Victoria Zuk; Alexandra Kucher; Chris Cotoi; Nicholas Hobson; Michael Sevestre; Mark W Skinner; Alfonso Iorio Journal: JMIR Hum Factors Date: 2022-03-02
Authors: Mairead O'Donovan; Eimear Quinn; Kate Johnston; Evelyn Singleton; Julie Benson; Brian O'Mahony; Declan Noone; Cleona Duggan; Ruth Gilmore; Kevin Ryan; James S O'Donnell; Niamh M O'Connell; Johnny Mahlangu Journal: Res Pract Thromb Haemost Date: 2021-10-11
Authors: Megan Kennedy; Brian O' Mahony; Sheila Roche; Mark McGowan; Evelyn Singleton; Kevin Ryan; Niamh M O' Connell; Steven W Pipe; Michelle Lavin; James S O' Donnell; Peter L Turecek; John Gormley Journal: Eur J Haematol Date: 2022-03-30 Impact factor: 3.674